# Chigene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chigene

- Industry: Healthcare
- Headquarters: Beijing, China
- Website: www.chigene.cn
- Total disclosed funding: $45M
- Latest round: Series B (Oct 1, 2021)
- Investors on record: 8

## About

Based in Beijing, China and established in 2012, Chigene is precision medicine company that provides gene and life omics big data precision medicine, tumor precision targeting and neoantigen immunization diagnosis and treatment. The company has built the world's largest database of genotype-phenotype associated genetic diseases for the Chinese population, and developed the world’s first genetic diagnostic platform based on the big data analysis of human genome. It has developed a full spectrum of next generation sequencing (NGS) based sequencing products for tumor therapeutics. Along with the sister company Chineo, perfected the neoantigen technology, it offers personalized immuno-therapies for cancer treatment. Up to 2021, it has been collaborating with more than 100 hospitals national wide, and working along with them towards the goal of building big data based medical diagnostic platform. It also has  been collaborating with national medical associations, and the goal of building the genetic diagnostic platform based on the Chinese population.

The company has a complete product line to provide an one-stop solution for precision medicine, covering highly integrated sequencing solution for diagnosis, prevention, and management of Mendelian inheritance disease, birth-defects, tumors, chronic diseases, pharmacogenomics, and other health care practices.

## Funding rounds

- Series B, Oct 1, 2021, $16M — Flyfot Ventures, Foison Capital
- Series B, Feb 10, 2021, $15M — Flyfot Ventures, 3E Bioventures Capital, Yijing Investment
- Series A, Dec 14, 2016, $14M — Fortune Capital, Source Capital, Alwin Capital, Shanghai Fosun Pharmaceutical (Group)

## Investors

- Fortune Capital — Series A
- Source Capital — Series A
- Alwin Capital — Series A
- Shanghai Fosun Pharmaceutical (Group) — Series A
- Flyfot Ventures (https://capitalatlas.ai/funds/flyfot-ventures) — Series B
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series B
- Foison Capital (https://capitalatlas.ai/funds/foison-capital) — Series B